Werewolf Therapeutics reports 37.5% response rate for WTX-124 combination in previously treated lung cancer patients
HOWL•Werewolf Therapeutics reported a 37.5% response rate for WTX-124 combination treatment in previously treated lung cancer patients. The company also reported trial findings for WTX-124 and WTX-330 presented at a November 7, 2026, meeting.
1. Trial findings
Werewolf Therapeutics reported cancer trial results presented at the Society for Immunotherapy of Cancer’s annual meeting on November 7, 2026. WTX-124 showed durable tumor responses as a monotherapy or with pembrolizumab in previously treated patients with advanced solid tumors.
2. Dosing and safety
The FDA aligned with the recommended Phase 2 dose for WTX-124, which was administered safely in outpatient settings. WTX-330 was well tolerated with an optimized formulation and showed tumor shrinkage in patients with advanced, treatment-resistant cancers. Neither drug showed evidence of vascular leak syndrome or recurrence of prior immune-related adverse events.
